Top

Published in:

Open Access 01-10-2016 | Short Communication

Does Weight Impact Anidulafungin Pharmacokinetics?

Authors: Vincent J. Lempers, Anne van Rongen, Eric P. van Dongen, Bert van Ramshorst, David M. Burger, Rob E. Aarnoutse, Catherijne A. Knibbe, Roger J. Brüggemann

Published in: Clinical Pharmacokinetics | Issue 10/2016

Abstract

Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index >40 kg/m²). Anidulafungin exposure was on average 32.5 % lower compared with the general patient population, suggesting dose increases may be required in this population.

Available only for authorised users

Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431–7.CrossRef

Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;6(55):149–67.CrossRef

European Medicines Agency (EMA). Ecalta; summary of product characteristics (last updated: 04/08/2015). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000788/WC500020673.pdf. Accessed 3 Apr 2016.

Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44(6):590–8.CrossRefPubMed

Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol. 2007;47(3):305–14.CrossRefPubMed

Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007;47(4):461–70.CrossRefPubMed

Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. Antimicrob Agents Chemother. 2013;57(4):1672–6.CrossRefPubMedPubMedCentral

Brüggemann RJ, Van Der Velden WJ, Knibbe CA, Colbers A, Hol S, Burger DM, et al. A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. J Antimicrob Chemother. 2015;70(4):1166–74.PubMed

Liu P, Mould DR. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother. 2014;58(8):4718–26.CrossRefPubMedPubMedCentral

10.

Liu P. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections. Antimicrob Agents Chemother. 2013;57(1):466–74.CrossRefPubMedPubMedCentral

11.

Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.CrossRefPubMed

12.

Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2011;55(11):5107–12.CrossRefPubMedPubMedCentral

13.

Hall RG 2nd, Swancutt MA, Meek C, Leff R, Gumbo T. Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother. 2013;57(5):2259–64.CrossRefPubMedPubMedCentral

Title: Does Weight Impact Anidulafungin Pharmacokinetics?
Authors: Vincent J. Lempers
Anne van Rongen
Eric P. van Dongen
Bert van Ramshorst
David M. Burger
Rob E. Aarnoutse
Catherijne A. Knibbe
Roger J. Brüggemann
Publication date: 01-10-2016
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 10/2016
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-016-0401-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Does Weight Impact Anidulafungin Pharmacokinetics?

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2016

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

How ‘Optimal’ are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations

Pharmacodynamic Analysis of Morphine Time-to-Remedication Events in Infants and Young Children After Congenital Heart Surgery

Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers

Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients